Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial

Open access
Hylander, Terese, Larsson, Olivia, Petersson-Westin, Ulla, Eriksson, Mia, Kumlien Georén, Susanna, Winqvist, Ola, Cardell, Lars-Olaf · 2016 · Respiratory Research

Abstract

BACKGROUND: Allergen-specific immunotherapy represents the only disease-modifying treatment for allergic diseases. We and others have previously demonstrated that intralymphatic immunotherapy (ILIT), a less time-consuming alternative to conventional subcutaneous immunotherapy (SCIT), is safe and effective. However, this has recently been disputed. The aim of this study was therefore to expand our previous trial, further assessing the safety and efficacy of ILIT. METHODS: Thirty-six patients with pollen-induced rhinoconjunctivitis were randomised to receive three intralymphatic inguinal injections of active allergen (1000 SQ-U birch- or grass-pollen) or placebo. Clinical effects, safety and circulating immunological markers were assessed before, 4 weeks after treatment and at the end of the consecutive pollen season. RESULTS: No moderate or severe reactions were recorded following ILIT. Patients receiving active ILIT experienced a significant improvement in self-recorded seasonal allergic symptoms, as compared to placebo (p = 0.05). In a subgroup of these patients ("improved"), a reduction in nasal symptoms following nasal allergen provocation was also demonstrated. No changes in total IgE or IgG4 were found. However, the affinity of allergen specific IgG4 following active treatment was significantly increased, as compared to non-improved patients (p = 0.04). This could be correlated with clinical improvement, on an individual level. CONCLUSIONS: This double-blinded placebo-controlled study confirms that ILIT is a safe and effective treatment for pollen-induced rhinoconjunctivitis, markedly reducing seasonal allergic symptoms. TRIAL REGISTRATION: EudraCT: 2009-016815-39.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12931-016-0324-9

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow diagram of study cohort. ILIT: Intralymphatic immunotherapy
Fig. 1 Flow diagram of study cohort. ILIT: Intralymphatic immunotherapyCC BY · PubMed Central
Fig. 2 Patient-recorded treatment outcome following three intralymphatic injections with active ILIT or placebo. Patients compared seasonal allergic symptoms after treatment, with symptoms prior to treatment. A VAS-score of 0 indicates no improvement, whereas a score of 10 indicates complete recovery. The black box signifies “improved” patients with a VAS-score above 5; the grey box signifies “non-improved” patients with a VAS-score below 1. Circles represent patients with an allergy towards birch pollen; triangles represent patients with an allergy towards grass pollen. *p < 0.05 using an Unpaired t test. ILIT: Intralymphatic immunotherapy
Fig. 2 Patient-recorded treatment outcome following three intralymphatic injections with active ILIT or placebo. Patients compared seasonal allergic symptoms after treatment, with symptoms prior to treatment. A VAS-score of 0 indicates no improvement, whereas a score of 10 indicates complete recovery. The black box signifies “improved” patients with a VAS-score above 5; the grey box signifies “non-improved” patients with a VAS-score below 1. Circles represent patients with an allergy towards birch pollen; triangles represent patients with an allergy towards grass pollen. *p < 0.05 using an Unpaired t test. ILIT: Intralymphatic immunotherapyCC BY · PubMed Central
Fig. 3 Levels of circulating immunoglobulins. IgE (a-b) and IgG4 (c-d) were measured before treatment, four weeks after treatment and after the consecutive pollen season in patients treated with active ILIT (a, c) or placebo (b, d). Analysis was performed using a repeated measures ANOVA. ILIT: Intralymphatic immunotherapy
Fig. 3 Levels of circulating immunoglobulins. IgE (a-b) and IgG4 (c-d) were measured before treatment, four weeks after treatment and after the consecutive pollen season in patients treated with active ILIT (a, c) or placebo (b, d). Analysis was performed using a repeated measures ANOVA. ILIT: Intralymphatic immunotherapyCC BY · PubMed Central
Fig. 4 Identification and nasal symptom scores of improved and non-improved patients. a Identification of patients reporting change in allergic symptoms 30 min after nasal allergen provocation (NPT), as well as change of seasonal allergic symptoms (VAS-score 0 = no improvement; VAS-score: 10 = complete recovery) after treatment. “Improved” patients are depicted with a black box. Non-improved patients are depicted with a grey box. b Self-reported allergic symptoms 30 min after nasal allergen provocation before treatment, four weeks after treatment and following the consecutive pollen season in improved, non-improved and placebo patients *p < 0.05 using a repeated measures ANOVA followed by a Dunnet’s multiple comparison post-test. ILIT: Intralymphatic immunotherapy
Fig. 4 Identification and nasal symptom scores of improved and non-improved patients. a Identification of patients reporting change in allergic symptoms 30 min after nasal allergen provocation (NPT), as well as change of seasonal allergic symptoms (VAS-score 0 = no improvement; VAS-score: 10 = complete recovery) after treatment. “Improved” patients are depicted with a black box. Non-improved patients are depicted with a grey box. b Self-reported allergic symptoms 30 min after nasal allergen provocation before treatment, four weeks after treatment and following the consecutive pollen season in improved, non-improved and placebo patients *p < 0.05 using a repeated measures ANOVA followed by a Dunnet’s multiple comparison post-test. ILIT: Intralymphatic immunotherapyCC BY · PubMed Central
Fig. 5 Change in IgG4 levels and affinity in improved and non-improved patients. a Levels of circulating IgG4 in improved and non-improved actively treated patients, as well as placebo patients, before treatment, four weeks after treatment and following the consecutive pollen season. Analysis was performed using a repeated measures ANOVA. b IgG4 affinity in improved and non-improved patients, measured and presented as percent allergen-bound IgG4 with increasing concentrations of ammonium thiocyanate (NH4SCN). n = 3–7 *p < 0.05 using two-way ANOVA followed by Fisher’s LSD
Fig. 5 Change in IgG4 levels and affinity in improved and non-improved patients. a Levels of circulating IgG4 in improved and non-improved actively treated patients, as well as placebo patients, before treatment, four weeks after treatment and following the consecutive pollen season. Analysis was performed using a repeated measures ANOVA. b IgG4 affinity in improved and non-improved patients, measured and presented as percent allergen-bound IgG4 with increasing concentrations of ammonium thiocyanate (NH4SCN). n = 3–7 *p < 0.05 using two-way ANOVA followed by Fisher’s LSDCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 92

Metadata

Authors
Hylander, T., Larsson, O., Petersson-Westin, U., Eriksson, M., Kumlien Georén, S., Winqvist, O., & Cardell, L.-O.
Affiliations
  • Karolinska Institutet (SE)
  • Lund University (SE)
  • Karolinska University Hospital (SE)
Corresponding author
Cardell, Lars-Olaf
Venue
Respiratory Research
Published
2016-01-27
Volume
17
Issue
1
Pages
10-10
ISSN
  • 1465-9921 (ISSN-L)
  • 1465-993X
OpenAlex
W2269234188
Cited by
92
References
24
Citations by year
2026: 4 · 2025: 2 · 2024: 4 · 2023: 12 · 2022: 12 · 2021: 9 · 2020: 20 · 2019: 4 · 2018: 11 · 2017: 9 · 2016: 5
FWCI
9.14
Type
journal article
Language
en
Open access
Locations
  • Respiratory Research (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
  • Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
Keywords
intralymphatic immunotherapy, allergen immunotherapy, birch pollen, grass pollen, allergen-specific IgG4, IgE, treatment safety
MeSH terms
Adult, Allergens, Conjunctivitis, Desensitization, Immunologic, Double-Blind Method, Female, Rhinitis, Allergic, Seasonal, Humans, Injections, Intralymphatic, Male, Middle Aged, Placebo Effect, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial. https://app.cochat.ai/papers/10.1186/s12931-016-0324-9
The paper
Hylander, T., Larsson, O., Petersson-Westin, U., Eriksson, M., Kumlien Georén, S., Winqvist, O., & Cardell, L.-O. (2016). Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial. Respiratory Research. https://doi.org/10.1186/s12931-016-0324-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.